MAZE · Maze Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 |
|---|---|---|---|---|---|
| Revenue | $20.00M | - | $2.50M | $0 | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $34.15M | - | $25.19M | $19.55M | $21.88M |
| SG&A | $12.40M | - | $6.87M | $5.90M | $6.14M |
| Total Operating Expenses | $46.55M | - | $26.73M | $25.45M | $28.01M |
| D&A | $444.0K | - | - | - | $950.0K |
| Operating Income | ($26.55M) | - | ($32.97M) | $139.56M | ($28.01M) |
| Interest Expense | $866.0K | - | - | - | - |
| Income Tax | - | - | $0 | $1.73M | - |
| Net Income | ($24.21M) | - | ($24.75M) | $139.06M | ($32.49M) |
| EPS - Basic | ($0.45) | - | ($10.25) | $5.92 | ($13.91) |
| EPS - Diluted | ($0.45) | - | ($10.25) | ($0.77) | ($13.91) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 |
|---|---|---|---|---|---|
| Cash & Equivalents | $198.77M | $189.25M | $149.61M | $264.54M | $196.81M |
| Accounts Receivable | $20.00M | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $4.01M | $1.79M | $2.92M | $3.67M | $2.40M |
| Current Assets | $379.78M | $349.72M | $391.30M | $271.15M | $201.67M |
| Total Assets | $419.71M | $397.13M | $422.06M | $303.52M | $240.54M |
| Current Liabilities | $21.24M | $22.56M | $22.11M | $19.90M | $20.67M |
| Long-term Debt | $38.83M | - | - | - | - |
| Total Liabilities | $78.01M | $42.16M | $42.62M | $41.28M | $40.77M |
| Stockholders' Equity | $341.70M | $354.97M | $379.44M | $262.24M | ($311.18M) |
| Retained Earnings | ($513.75M) | ($489.55M) | ($454.98M) | ($424.89M) | ($358.43M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($39.11M) | - | - | - | ($23.44M) |
| Investing Cash Flow | $6.28M | - | - | - | ($279.0K) |
| Financing Cash Flow | $42.36M | - | - | - | $24.58M |
| CapEx | $93.0K | - | - | - | $279.0K |
| Free Cash Flow | ($39.21M) | - | - | - | ($23.72M) |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | -132.8% | - | -1318.6% | - | - |
| EBITDA margin | -130.5% | - | - | - | - |
| Net margin | -121.0% | - | -990.1% | - | - |
| Free cash flow margin | -196.0% | - | - | - | - |
| FCF / Net income | 1.62 | - | - | - | 0.73 |
| R&D / Revenue | 170.7% | - | 1007.6% | - | - |
| SG&A / Revenue | 62.0% | - | 274.9% | - | - |
| Effective tax rate | - | - | - | 1.2% | - |
| Return on assets | -5.8% | - | -5.9% | 45.8% | -13.5% |
| Return on equity | -7.1% | - | -6.5% | 53.0% | 10.4% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 17.88 | 15.50 | 17.70 | 13.63 | 9.76 |
| Quick ratio | 17.88 | 15.50 | 17.70 | 13.63 | 9.76 |
| Cash ratio | 9.36 | 8.39 | 6.77 | 13.29 | 9.52 |
| Leverage | |||||
| Debt / Equity | 0.11 | - | - | - | - |
| Debt / Assets | 0.09 | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | -30.7x | - | - | - | - |
| Equity multiplier | 1.23 | 1.12 | 1.11 | 1.16 | -0.77 |
| Liabilities / Assets | 0.19 | 0.11 | 0.10 | 0.14 | 0.17 |
| Efficiency | |||||
| Asset turnover | 0.05 | - | 0.01 | 0.00 | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | 365d | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 4.7x | - | 0.2x | 0.2x | - |
| P / S | 80.4x | - | 25.1x | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | 5.2% | - | - | - | - |
| Net income growth (YoY) | 25.5% | - | - | - | - |
| EPS growth (YoY) | 96.8% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | -65.3% | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Maze Therapeutics against the 5 most active filers in the same SIC group.